June 24, 2025

Exam Shift Spurs National Rights Battle

Democratic AGs push to relocate OB-GYN exams from Texas, citing threats to reproductive and gender-affirming care under state abortion bans.

KFF Health News

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 23, 2025

Older Adults Lead Vaccine Comeback

Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.

KFF Health News

June 20, 2025

FDA Approves First Twice-Yearly Injectable PrEP

FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.

Conexiant

June 19, 2025

FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma

The FDA has approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

The ASCO Post

June 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap NDA for the Treatment of DED

Per FDA agreement, the only new clinical data included in the resubmitted new drug application were from the recently completed dry eye chamber trial, which achieved the primary endpoint, according to the company.

Ophthalmology Management

June 16, 2025

Can One Drug Decode Obesity’s Roots?

A new treatment for rare, extreme hunger offers life-changing relief and uncovers clues to obesity’s tangled biology—reshaping how we understand and treat the condition.

KFF Health News

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant

June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant